Catalyst Pharmaceuticals (CPRX) Receivables (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Receivables of $130.8 million for Q1 2026, up 3.44% on a QoQ basis from $126.5 million in Q4 2025, and up 83.59% year-over-year from $71.3 million in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Receivables (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Receivables history runs 9 years deep, the most recent figure standing at $130.8 million for Q1 2026.
- Quarterly Receivables rose 83.59% year-over-year to $130.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.8 million (up 83.59% YoY) and the FY2025 annual result came in at $126.5 million, up 93.17% from the prior year.
- Receivables was $130.8 million for Q1 2026 at Catalyst Pharmaceuticals, up from $126.5 million in the prior quarter.
- Across five years, Receivables topped out at $130.8 million in Q1 2026 and bottomed at $9.3 million in Q3 2022.
- A 5-year average of $56.5 million and a median of $57.2 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables soared 414.61% — and 2025, when it advanced 15.2%.
- Catalyst Pharmaceuticals' Receivables stood at $10.4 million in 2022, then jumped by 412.64% to $53.5 million in 2023, then climbed by 22.35% to $65.5 million in 2024, then surged by 93.17% to $126.5 million in 2025, then grew by 3.44% to $130.8 million in 2026.
- Business Quant data shows CPRX's Receivables at $130.8 million in Q1 2026, $126.5 million in Q4 2025, and $106.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 130.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130.83 Mn |
| Dec 31, 2025 | 126.48 Mn |
| Sep 30, 2025 | 106.41 Mn |
| Jun 30, 2025 | 65.86 Mn |
| Mar 31, 2025 | 71.27 Mn |
| Dec 31, 2024 | 65.48 Mn |
| Sep 30, 2024 | 58.27 Mn |
| Jun 30, 2024 | 57.17 Mn |
| Mar 31, 2024 | 60.49 Mn |
| Dec 31, 2023 | 53.51 Mn |
| Sep 30, 2023 | 48.05 Mn |
| Jun 30, 2023 | 42.80 Mn |
| Mar 31, 2023 | 33.40 Mn |
| Dec 31, 2022 | 10.44 Mn |
| Sep 30, 2022 | 9.34 Mn |
| Jun 30, 2022 | 9.59 Mn |
| Mar 31, 2022 | 10.55 Mn |
| Dec 31, 2021 | 6.62 Mn |
| Sep 30, 2021 | 6.63 Mn |
| Jun 30, 2021 | 6.29 Mn |